Rheumatoid Arthritis:
Early Diagnosis, Medications & Treatment Management

At a glance

Affected in Germany~550,000 adults (DGRh); women affected ~3× more often
Age at onsetUsually middle adulthood; possible at any age
CauseAutoimmune disease — the immune system attacks the joint lining (synovium)
Treatment goalRemission (treat-to-target) — the earlier treatment begins, the better the long-term outlook
Medications (selection)Methotrexate as the base therapy, DMARDs, biologics, JAK inhibitors, biosimilars
ICD-10M05 (seropositive), M06 (seronegative)

Table of contents

  1. What is rheumatoid arthritis?
  2. Symptoms — early detection saves joints
  3. Causes and risk factors
  4. Diagnosis: why see a rheumatologist quickly?
  5. Medications: step therapy & treat-to-target
  6. Treatment without medication
  7. Fatigue and mental strain
  8. Living with rheumatoid arthritis
  9. How brite helps you
  10. FAQ
  11. Related topics

1. What is rheumatoid arthritis?

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the immune system mistakenly attacks the joint lining (synovium). The result is inflammation, swelling and pain — without treatment, progressive joint damage can occur.

Unlike osteoarthritis — which is more a matter of joint wear — RA is an inflammatory systemic disease. It can also affect structures outside the joints (lungs, heart, eyes, blood vessels). Typical features are a course that comes in flares and a usually symmetrical involvement of the small joints in the hands and feet.¹

Window of opportunity — the first months are decisive With early diagnosis and modern medications (biologics, JAK inhibitors), a relevant proportion of those affected can achieve remission. The earlier targeted treatment begins, the better the long-term outlook usually is.¹˒²

2. Symptoms — early detection saves joints

Early symptoms — don't ignore them

  • Morning joint stiffness lasting markedly longer than usual — an important early sign and a clue distinguishing it from osteoarthritis
  • Swelling and warmth in small joints — typically the knuckle (MCP) and middle (PIP) finger joints, the base joints of the toes and the wrists
  • Symmetrical involvement — the same joints affected on both sides
  • Joint pain — often worst at night and in the morning, improving with movement
  • Pain when the knuckle joints are squeezed sideways (Gaenslen's sign)
  • Fatigue — pronounced exhaustion, experienced by many as particularly burdensome
  • A flu-like feeling of illness, a slightly raised temperature
  • Occasionally: carpal tunnel syndrome as the first sign of RA

Late symptoms (without adequate treatment)

  • Joint deformities (e.g. ulnar deviation of the fingers, swan-neck or boutonnière deformity)
  • Rheumatoid nodules — firm lumps under the skin (elbows, fingers, heel)
  • Involvement of other organs (interstitial lung disease, pericarditis, eye inflammation)
  • Increased cardiovascular risk — RA is considered an independent cardiovascular risk factor
With swelling + morning stiffness for several weeks: see a rheumatologist promptly Every week without targeted treatment can potentially contribute to permanent joint damage. The first months after symptoms begin often determine the long-term outlook.¹

3. Causes and risk factors

  • Genetic predisposition: Certain HLA genes (including HLA-DR4) are the most important genetic risk factors — but not everyone with them develops RA
  • Smoking: The most important modifiable risk factor. It can significantly increase the risk of RA and worsen the response to methotrexate and biologics. Quitting smoking can support treatment.¹˒³
  • Sex: Women are affected about three times as often as men
  • Periodontitis: Evidence of a link with the development of RA
  • Excess weight: Can increase the risk of disease and impair the response to treatment
  • Autoantibodies (rheumatoid factor, anti-CCP) can be detectable years before the first symptoms

4. Diagnosis: why see a rheumatologist quickly?

An early diagnosis is considered key to the further course of RA. The goal is usually to begin treatment within a few months of symptom onset. The ACR/EULAR criteria are often used for classification.¹˒²

Laboratory tests

  • CRP and ESR (inflammatory markers): Often elevated in active RA. Important: normal values do not rule out RA.
  • Anti-CCP antibodies: An important serological marker with high specificity. Can be positive years before the first symptoms — and also has prognostic significance.
  • Rheumatoid factor (RF): Positive in a large proportion of RA patients, but less specific than anti-CCP. Seropositive = RF and/or anti-CCP detectable.
  • Blood count: Anemia of chronic disease is common; raised platelets are possible.

Imaging

Joint ultrasound (arthrosonography) — standard in practice
Can reveal synovitis and small joint effusions early — often before clear swelling is clinically visible. Quick, with no radiation exposure.
MRI — especially sensitive for early erosions
Especially sensitive for early erosions and bone marrow edema — changes that are often not yet visible on X-ray. Usually used in unclear cases.
X-ray (hands and feet)
Usually shows changes only in later stages. Important as a baseline finding and for monitoring over time.

Learn more: Preparing for a doctor's appointment.

5. Medications: step therapy and treat-to-target

Drug treatment today usually follows the principle of "treat-to-target" (T2T): the goal is remission or at least low disease activity — with regular checks and adjustments until the target is reached.¹

Step 1 Conventional synthetic DMARDs (csDMARDs)
Methotrexate (MTX) — the base therapy for RA
The gold standard of base therapy for many years.
Dosing: Only once a week (not daily!) — as a tablet or subcutaneous injection
Folic acid: Usually prescribed on an individually defined schedule — significantly reduces side effects
Onset of action: Usually after a few weeks
Side effects: Nausea, mouth ulcers, changes in liver values — regular blood tests are standard
⚠ No alcohol while on MTX (liver toxicity)
⚠ Strictly contraindicated when trying to conceive and in pregnancy — always clarify details with your rheumatology team¹
Leflunomide
An alternative if MTX is not tolerated. Regular blood tests are recommended. It usually stays in the body for a long time — relevant when changing treatment.
Sulfasalazine and hydroxychloroquine
Further conventional drugs — either in combination with MTX or as an alternative. With hydroxychloroquine, regular eye examinations are usually recommended.
Step 2 Biologics and JAK inhibitors — for an inadequate response

If a conventional base therapy doesn't reach the treatment goal after a few months, current guidelines often add targeted therapies (usually on top of MTX). Biologics and JAK inhibitors are considered equivalent options.¹

Biologics (bDMARDs)

TNF-alpha inhibitors
Active ingredients: adalimumab, etanercept, infliximab, certolizumab, golimumab
They block the inflammatory messenger TNF-alpha. Given as an injection at certain intervals or as an infusion. Biosimilars are available for several of these drugs.
IL-6 receptor antagonists
Active ingredients: tocilizumab, sarilumab
A good option when CRP is strongly elevated and systemic inflammation is pronounced. Tocilizumab is also approved as monotherapy without MTX — a possible advantage if MTX is not tolerated.
Other biologics
Abatacept (a T-cell co-stimulation modulator) — a different mechanism of action, with a favorable safety profile.
Rituximab (B-cell depletion) — typically used when the response to other biologics is inadequate; given as an infusion in certain cycles.

JAK inhibitors (tsDMARDs)

JAK inhibitors — as tablets
They intervene in the intracellular signaling pathways of inflammation. Possible advantage: taken as a tablet rather than an injection/infusion; a comparatively fast onset of action.
Active ingredients available in Germany: tofacitinib, baricitinib, upadacitinib, filgotinib
Before starting and during treatment: regular blood tests are needed (blood count, liver values, thromboembolism risk).¹
Safety note on JAK inhibitors (ORAL Surveillance study) The ORAL Surveillance study found, in patients with certain cardiovascular risk factors taking tofacitinib, evidence of an increased risk of thromboembolisms (blood clots) and certain cancers. EULAR and German professional societies therefore recommend preferring biologics over JAK inhibitors in at-risk patients (older age, cardiovascular risk factors). The individual decision is always made by your rheumatology team.⁶

Biosimilars

Biosimilars are biotechnologically produced follow-on products of biologics, with comparable efficacy and a comparable safety profile. According to guidelines, switching is generally considered safe and can help reduce treatment costs. Learn more: Generics vs. brand-name.¹

Supportive treatment

Cortisone (glucocorticoids) — only short-term as a bridge
Usually given at a low dose and only as a short-term bridge until a DMARD therapy reaches its full effect. According to current guidelines, long-term high-dose cortisone therapy should usually be avoided. Learn more: Stopping cortisone.
NSAIDs (e.g. ibuprofen, diclofenac) — only as a bridge
Can help relieve pain but have no disease-modifying effect. Only as a bridge and as needed; with longer use, gastric protection is often sensible. Learn more: Stomach problems from medication.
Never stop DMARDs, biologics or JAK inhibitors on your own A relapse can damage the joints quickly and sometimes permanently. Always discuss changes with your rheumatology team. Learn more: Stopping medication, Check interactions.

6. Treatment without medication

  • Physiotherapy: A central component — preserving joint function, relieving pain, strengthening muscles. During acute flares, adapted, pain-guided movement rather than strict rest.
  • Occupational therapy: Joint-protection training, assistive devices (e.g. thicker grips), splints. Goal: making everyday tasks easier.
  • Exercise and sport: Joint-friendly activities (swimming, cycling, yoga, moderate strength training) are considered an important part of treatment and can have a positive effect on fatigue.
  • Diet: A Mediterranean-style, anti-inflammatory diet (vegetables, fruit, olive oil, nuts, fish with omega-3) can sensibly complement treatment — but does not replace drug therapy.
  • Quitting smoking: One of the most important non-drug measures. Smoking worsens the course and the response to medications.¹

7. Fatigue and mental strain

Fatigue — an abnormal exhaustion — is common in RA and is experienced by many as a particularly burdensome symptom. It can't be "rested away" with simple sleep and differs markedly from normal tiredness.¹˒³

Depression and anxiety occur more often in people with RA than in the general population. What helps according to current evidence: regular physical activity (one of the strongest effects against fatigue), sleep hygiene, targeted stress management, pacing (deliberately budgeting your energy) and psychological support if needed. Fatigue is a real symptom of the disease — it's worth actively raising the topic with your rheumatology team.

8. Living with rheumatoid arthritis

  • Work: Most occupations are possible with well-controlled RA. Ergonomic adjustments can be helpful. With a recognized degree of disability, special employment-law protections may apply (in Germany, via the inclusion office / Integrationsamt).
  • Flares: Cooling, pain-guided movement and early consultation with your rheumatology team are sensible.
  • Vaccinations: During immunosuppressive therapy, certain vaccinations are especially important. Live vaccines are generally not recommended during immunosuppression. Have your vaccination status reviewed and completed before starting treatment.
  • Cardiovascular risk: RA is considered an independent cardiovascular risk factor. Regular checks of blood pressure, blood lipids and blood sugar are sensible. Effective RA treatment can also influence cardiovascular risk.¹
  • Alcohol: While on methotrexate, particular caution is generally advised (liver toxicity). Learn more: Medication and alcohol.

How brite helps you with rheumatoid arthritis

Methotrexate once a week, folic acid the next day, the biologic injection at fixed intervals — brite keeps track of it all.

  • Medication reminders — Methotrexate once a week, folic acid the next day, the biologic injection at fixed intervals, JAK inhibitors daily: brite reminds you reliably. Set up a reminder
  • Interaction check — Check MTX, biologics and JAK inhibitors in combination with other medications or vaccinations for free. Check now
  • Health tracking — Record flares, joint pain, morning stiffness, fatigue and blood values in a structured way. Track your history
  • Digital medication plan — all your medications clearly laid out for your rheumatology team, GP and pharmacy. Go to medication plan
Get started for free
brite app

FAQ: Common questions about rheumatoid arthritis

In the classic sense, rheumatoid arthritis cannot be cured. With modern, early treatment, a relevant proportion of those affected can achieve remission or at least low disease activity. Early diagnosis and consistent treat-to-target are crucial.¹
RA is an autoimmune disease with inflammation that mainly affects the small joints symmetrically and causes longer-lasting morning stiffness. Osteoarthritis, by contrast, is joint wear that mainly affects load-bearing joints (knees, hips); the morning stiffness is usually much shorter, and systemic inflammation is typically absent.
At the lower dose usual in RA, methotrexate has been established for decades and is well studied. Important safety points: take it only once a week (not daily!), with accompanying folic acid as your doctor directs, regular blood tests and strict avoidance of alcohol. MTX is strictly contraindicated in pregnancy and when trying to conceive.¹
Biologics are biotechnologically produced antibodies that can specifically block inflammatory messengers (e.g. TNF-alpha or IL-6). They are usually used when base therapy with MTX is not enough. Biosimilars are follow-on products of existing biologics with comparable efficacy and safety. According to current guidelines, switching is generally considered safe.¹
According to current guidelines, both groups are considered equally effective in many situations. JAK inhibitors are taken as tablets and often have a fast onset of action. In at-risk patients (older age, cardiovascular risk factors), the ORAL Surveillance study means a biologic is usually preferred. The individual decision is always made by your rheumatology team.¹˒⁶
Yes — exercise is considered one of the most important parts of RA treatment and has good evidence for fatigue, among other things. Joint-friendly activities such as swimming, cycling, yoga or moderate strength training are recommended. During acute flares, the activity level is adjusted but usually not paused completely.
Fatigue is an abnormal exhaustion that can't simply be slept off. It is partly driven by the immune system. What usually helps: regular exercise (the best evidence), pacing (deliberately budgeting your energy), good sleep hygiene, stress management and psychological support if needed — and an open conversation with your rheumatology team.
Smoking can significantly increase the risk of RA, worsen its course and reduce the response to methotrexate and biologics. It also adds to the already elevated cardiovascular risk. Quitting smoking is therefore considered one of the most effective single non-drug measures.¹˒³
With sustained remission, a step-by-step reduction in therapy may be considered — usually starting with cortisone, then possibly biologics or JAK inhibitors (e.g. by lengthening the intervals or reducing the dose). Methotrexate is usually kept on where possible. Stopping all DMARDs completely carries a relevant risk of relapse and should only be considered under close rheumatology supervision.¹

11. Related topics

Stopping cortisone Generics vs. brand-name (biosimilars) Medication and alcohol Stomach problems from medication Medication interactions Stopping medication Medication side effects

Sources

  1. S3 Guideline "Drug Therapy of Rheumatoid Arthritis" (DGRh et al., AWMF reg. no. 060-004, Version 3.0, January 2026). awmf.org
  2. EULAR Recommendations for the management of rheumatoid arthritis (2022 Update). ard.bmj.com
  3. Deutsche Rheuma-Liga (German Rheumatism League): Rheumatoid Arthritis — Patient Information and Guides. rheuma-liga.de
  4. German Society for Rheumatology and Clinical Immunology (DGRh). dgrh.de
  5. gesundheitsinformation.de (IQWiG): Rheumatoid Arthritis. gesundheitsinformation.de
  6. Ytterberg S. R. et al.: Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis (ORAL Surveillance), NEJM 2022. pubmed.ncbi.nlm.nih.gov
Medical disclaimer: This article is for general information only and is not a substitute for medical advice, diagnosis or treatment. The choice of medication and dosages are always determined individually by your treating doctor — usually in close coordination with a rheumatology practice or clinic. New joint swelling with morning stiffness for several weeks should be evaluated by a rheumatologist promptly. DMARDs, biologics and JAK inhibitors must not be stopped on your own. Last updated: April 2026.